HPV Vaccine for Low Lymphocyte Count

"To date, 16 Phase 3 trials are exploring this treatment, and 32 separate studies have been initiated. In Bangkok and Chang Wat Nonthaburi alone there are 244 clinical trial sites where research is taking place."

"This clinical trial is looking to enrol 100 individuals aged 18-70 with cd4 antigens. Participants must also be regularly using a hormonal method of contraception such as the pill, implant or injection (which needs to have been started at least 1 month before receiving their first dose) and are encouraged to use additional methods including diaphragms/cervical caps and condoms with spermicide."

"According to the clinicaltrials.gov database, this medical trial is open for recruitment and has been since February 4th 2019 (last updated on July 6th 2022)."

"Participants of this medical trial must be between 18 and 70 years old."

"This treatment is capable of targeting and treating infections stemming from Human Papillomavirus type 58, Human Papillomavirus type 31, and general HPV infection."

"Affirmative. According to data published on clinicaltrials.gov, this medical study was initially advertised in February of 2019 and has been actively recruiting since then. The trial is hoping to enroll a total of 100 participants at one location."

"At Power, the safety of this therapy has been assigned a score of 2. This is because while there are some findings that suggest it may be safe to use, no evidence points towards its efficacy at present."

"Investigations into this medication have been ongoing since 2002, when Merck Sharp & Dohme Corp. sponsored the first study which included 12167 participants. Thanks to its successful conclusion in Phase 3 trials, it has achieved drug approval and is now being trialled at 32 sites spanning 129 cities and 32 countries worldwide."